Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natural History and Management of VHL Associated Pancreatic Neuroendocrine Tumors
NCT04074135Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2020
- Primary completion
- Jan 2036
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gallium ga 68 dotatate in von Hippel–Lindau disease (VHL), Pancreatic neuroendocrine tumor (PanNET), sponsored by National Cancer Institute. Started Jun 2020; status: recruiting.
02
Drugs
gallium ga 68 dotatate
03
Conditions
von Hippel–Lindau disease (VHL)Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT04074135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074135.